If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
== Diseases and disorders == The following sections describe how imbalances or dysfunction in specific neurotransmitters—dopamine, serotonin, and glutamate—have been tentatively linked to various mental or neurological disorders.
=== World War I and aftermath === During World War I, what later became known as the Sudetenland experienced a rate of war deaths that was higher than most other German-speaking areas of Austria-Hungary and exceeded only by German South Moravia and Carinthia. Thirty-four of each 1,000 inhabitants were killed. Austria-Hungary broke apart at the end of World War I. In late October 1918, an independent Czechoslovak state, consisting of the lands of the Bohemian kingdom and areas belonging to the Kingdom of Hungary, was proclaimed. The German deputies of Bohemia, Moravia, and Silesia in the Imperial Council (Reichsrat) referred to the Fourteen Points of US President Woodrow Wilson and the right proposed therein to self-determination and attempted to negotiate the union of the German-speaking territories with the new Republic of German Austria, which itself aimed at joining Weimar Germany. The German-speaking parts of the former Lands of the Bohemian Crown were to be part of a newly created Czechoslovakia, a multi-ethnic state of several nations: Czechs, Germans, Slovaks, Hungarians, Poles and Ruthenians. On 20 September 1918, the Prague government asked for the opinion of the United States on the Sudetenland. Wilson sent Ambassador Archibald Coolidge into Czechoslovakia. Coolidge insisted on respecting the Germans' right to self-determination and uniting all German-speaking areas with either Germany or Austria, with the exception of northern Bohemia. However, the American delegation at the Paris talks decided not to follow Coolidge's proposal.
=== General and cited sources === Benn, James A. (2015). Tea in China: A Religious and Cultural History. Hong Kong University Press. ISBN 978-988-8208-73-9. Heiss, Mary Lou; Heiss, Robert J. (2007). The Story of Tea: A Cultural History and Drinking Guide. Ten Speed Press. ISBN 978-1-58008-745-2. Mair, Victor H.; Hoh, Erling (2009). The True History of Tea. Thames & Hudson. ISBN 978-0-500-25146-1. Martin, Laura C. (2007). Tea: The Drink that Changed the World. Tuttle Publishing. ISBN 978-0-8048-3724-8. OCLC 1159227468. OL 1956186W.
Minnich, V.; Na-Nakorn, S.; Chong-Chareonsuk, S.; Kochaseni, S. (January 1954). "Mediterranean anemia; a study of thirty-two cases in Thailand". Blood. 9 (1): 1–23. doi:10.1182/blood.V9.1.1.1. ISSN 0006-4971. PMID 13115468. Chernoff, Amoz I.; Minnich, Virginia; Chongchareonsuk, Soodsarkorn (1954). "Hemoglobin E, a Hereditary Abnormality of Human Hemoglobin". Science. 120 (3120): 605–606. Bibcode:1954Sci...120..605C. doi:10.1126/science.120.3120.605. JSTOR 1682300. PMID 13205193. Pica
Chronic use may result in cocaine dependence, withdrawal symptoms, neurotoxicity, and nasal damage, including cocaine-induced midline destructive lesions. Coca cultivation and initial processing occur primarily in Latin America, especially in the Andes regions of Bolivia, Peru, and Colombia. Cultivation is expanding into Central America, including Honduras, Guatemala, and Belize. Violence linked to the cocaine trade continues to affect Latin America and the Caribbean and is expanding into Western Europe, Asia, and Africa as transnational organized crime groups compete globally. Cocaine remains the world's fastest-growing illicit drug market. Coca chewing dates back at least 8,000 years in South America. Large-scale cultivation occurred in Taiwan and Java prior to World War II. The cocaine boom—a sharp rise in illegal production and trade—began in the late 1970s and peaked in the 1980s. Cocaine is regulated under international drug control conventions, though its legal status varies nationally: several countries have decriminalized possession of small quantities.
Sources: en.wikipedia.org
== Synthesis == PCP can be produced by the chlorination of phenol in the presence of catalyst (anhydrous aluminium or ferric chloride) and a temperature up to about 191 °C. This process does not result in complete chlorination and commercial PCP is only 84–90% pure. The main contaminants include other polychlorinated phenols, polychlorinated dibenzo-p-dioxins, and polychlorinated dibenzofurans. Some of these species are even more toxic than the PCP itself.
== Reformulation == Percodan was reformulated in 2005; prior to 2005, it contained two oxycodone salts—4.62 mg of oxycodone hydrochloride and 0.38 mg of oxycodone terephthalate. Since the latter salt is unusual in the pharmacopeia, the manufacturer increased the amount of oxycodone hydrochloride to 4.8355 mg and discontinued the oxycodone terephthalate.
As of August 2018, pembrolizumab is indicated for the treatment of those with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. In November 2018, the US FDA granted accelerated approval to pembrolizumab for those with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In February 2019, the US FDA approved pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. The FDA granted the application orphan drug designation. In June 2019, the US FDA granted accelerated approval to pembrolizumab for those with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy, and the FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Pembrolizumab was approved for use in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥ 1) as determined by an FDA‑approved test.
Its activation by the neurotransmitter glutamate facilitates rapid neuronal communication, essential for various brain functions, including learning and memory. Its name is derived from the ability to be activated by the artificial glutamate analog AMPA. The receptor was initially named the "quisqualate receptor" by Watkins and colleagues after the naturally occurring agonist quisqualate. Later, the receptor was designated as the "AMPA receptor" following the development of the selective agonist AMPA by Tage Honore and colleagues at the Royal Danish School of Pharmacy in Copenhagen. The GRIA2-encoded AMPA receptor ligand binding core (GluA2 LBD) was the first glutamate receptor ion channel domain to be crystallized.
==== Second state of emergency: June 1986 ==== The partial emergency was lifted on 7 March 1986, only to be replaced on 12 June – in the run-up to the tenth anniversary of the Soweto uprising on 16 June – by a second, far more stringent state of emergency, now applying across the country. Among other things, the new order empowered any member of the police or army to use any kind of force deemed necessary to clear an area. With the death toll by then "far in excess of 1,600", Botha told Parliament, "I am of the opinion that the ordinary laws of the land at present on the statute book are inadequate to enable the government to insure the security of the public and to maintain public order". The government said that it detained more than 1,000 people on the first day of the emergency; 30,000 were detained by August 1987. Indeed, the primary use of the emergency orders was to enable mass and indefinite detention of those viewed by the government as the ringleaders or instigators of the unrest. Critics of the government argued that this was deeply counterproductive, as the putative ringleaders were generally "simply the most articulate and experienced activists", the removal of whom "created a political vacuum into which unruly, undisciplined elements surged". In the phrase of the UDF's Murphy Morobe (speaking to press while in hiding to evade arrest), "Removing responsible leaders of the people has effectively paved the way for a blood bath". Desmond Tutu lamented as early as May 1986 that the government "have arrested the very people they should be talking to...
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.